JP2013513812A - アッセイ - Google Patents
アッセイ Download PDFInfo
- Publication number
- JP2013513812A JP2013513812A JP2012543890A JP2012543890A JP2013513812A JP 2013513812 A JP2013513812 A JP 2013513812A JP 2012543890 A JP2012543890 A JP 2012543890A JP 2012543890 A JP2012543890 A JP 2012543890A JP 2013513812 A JP2013513812 A JP 2013513812A
- Authority
- JP
- Japan
- Prior art keywords
- assay
- polypeptide
- mcm
- cells
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003556 assay Methods 0.000 title claims abstract description 62
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 39
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 39
- 102100033711 DNA replication licensing factor MCM7 Human genes 0.000 claims description 57
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 claims description 57
- 108010080146 androgen receptors Proteins 0.000 claims description 54
- 102000001307 androgen receptors Human genes 0.000 claims description 54
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 41
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 41
- 239000011230 binding agent Substances 0.000 claims description 39
- 239000000523 sample Substances 0.000 claims description 38
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 22
- 239000012472 biological sample Substances 0.000 claims description 20
- 210000002700 urine Anatomy 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 6
- 102100034001 DNA replication licensing factor MCM5 Human genes 0.000 claims description 5
- 101001017545 Homo sapiens DNA replication licensing factor MCM5 Proteins 0.000 claims description 5
- 102100039606 DNA replication licensing factor MCM3 Human genes 0.000 claims description 4
- 101000963174 Homo sapiens DNA replication licensing factor MCM3 Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 102100021389 DNA replication licensing factor MCM4 Human genes 0.000 claims description 2
- 102100033720 DNA replication licensing factor MCM6 Human genes 0.000 claims description 2
- 101000615280 Homo sapiens DNA replication licensing factor MCM4 Proteins 0.000 claims description 2
- 101001018484 Homo sapiens DNA replication licensing factor MCM6 Proteins 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 109
- 102000003794 Mini-chromosome maintenance proteins Human genes 0.000 description 37
- 108090000159 Mini-chromosome maintenance proteins Proteins 0.000 description 37
- 238000010186 staining Methods 0.000 description 31
- 239000000427 antigen Substances 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 210000005267 prostate cell Anatomy 0.000 description 16
- 210000000805 cytoplasm Anatomy 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000011534 wash buffer Substances 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000012758 nuclear staining Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 230000002280 anti-androgenic effect Effects 0.000 description 6
- 239000000051 antiandrogen Substances 0.000 description 6
- 238000012137 double-staining Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012099 Alexa Fluor family Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000000064 prostate epithelial cell Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 239000012110 Alexa Fluor 594 Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000012303 cytoplasmic staining Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000006148 magnetic separator Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000012801 analytical assay Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000033366 cell cycle process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000008948 male sex determination Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- -1 phosphors Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0921873.6A GB0921873D0 (en) | 2009-12-15 | 2009-12-15 | Assay |
| GB0921873.6 | 2009-12-15 | ||
| PCT/GB2010/002274 WO2011073619A1 (en) | 2009-12-15 | 2010-12-15 | Assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013513812A true JP2013513812A (ja) | 2013-04-22 |
| JP2013513812A5 JP2013513812A5 (enExample) | 2014-02-06 |
Family
ID=41667106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543890A Pending JP2013513812A (ja) | 2009-12-15 | 2010-12-15 | アッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130171662A1 (enExample) |
| EP (2) | EP2513651A1 (enExample) |
| JP (1) | JP2013513812A (enExample) |
| CN (1) | CN102782497A (enExample) |
| CA (1) | CA2807870A1 (enExample) |
| GB (1) | GB0921873D0 (enExample) |
| WO (1) | WO2011073619A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2806498T3 (es) | 2015-06-08 | 2021-02-17 | Arquer Diagnostics Ltd | Métodos para el análisis de una muestra de orina |
| EP4060344A1 (en) * | 2015-06-08 | 2022-09-21 | Arquer Diagnostics Limited | Methods and kits |
| GB201820868D0 (en) * | 2018-12-20 | 2019-02-06 | Arquer Diagnostics Ltd | Detection method |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307030B1 (en) * | 1988-04-15 | 2001-10-23 | The University Of North Carolina At Chapel Hill | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| CN1282422A (zh) * | 1997-10-21 | 2001-01-31 | 癌症研究行动技术有限公司 | 对细胞生长异常的测定 |
| US6303323B1 (en) * | 1997-10-21 | 2001-10-16 | Cancer Research Campaign Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6566130B1 (en) * | 2000-01-28 | 2003-05-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Androgen-regulated gene expressed in prostate tissue |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| US7666595B2 (en) * | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| US20060211059A1 (en) * | 2005-03-18 | 2006-09-21 | Taneja Samir S | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone |
| CN101239181A (zh) * | 2007-02-08 | 2008-08-13 | 中国科学院上海生命科学研究院 | 一种和癌症有关的组蛋白去甲基化酶及其应用 |
| GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
| GB0800311D0 (en) | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
| GB0811567D0 (en) * | 2008-06-24 | 2008-07-30 | Cytosystems Ltd | Assay |
-
2009
- 2009-12-15 GB GBGB0921873.6A patent/GB0921873D0/en not_active Ceased
-
2010
- 2010-12-15 JP JP2012543890A patent/JP2013513812A/ja active Pending
- 2010-12-15 US US13/512,823 patent/US20130171662A1/en not_active Abandoned
- 2010-12-15 EP EP10801208A patent/EP2513651A1/en not_active Ceased
- 2010-12-15 CA CA2807870A patent/CA2807870A1/en not_active Abandoned
- 2010-12-15 EP EP15185015.3A patent/EP2977762A3/en not_active Withdrawn
- 2010-12-15 CN CN2010800568880A patent/CN102782497A/zh active Pending
- 2010-12-15 WO PCT/GB2010/002274 patent/WO2011073619A1/en not_active Ceased
-
2014
- 2014-09-17 US US14/489,207 patent/US10267801B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| JPN5013005355; ＮＡＲＩＣＵＬＡＭ Ｊ: 'ＭＣＭ-２ ＥＸＰＲＥＳＳＩＯＮ ＩＮ ＣＬＩＮＩＣＡＬＬＹ ＬＯＣＡＬＩＳＥＤ ＰＲＯＳＴＡＴＥ ＣＡＮＣＥＲ' ＥＵＲＯＰＥＡＮ ＵＲＯＬＯＧＹ ＳＵＰＰＬＥＭＥＮＴＳ Ｖ７ Ｎ３, 20080301, Ｐ２５５ * |
| JPN5013005357; ＯＵＴＩ ＳＡＲＡＭＡＫＩ: 'ＣＨＲＯＭＯＳＯＭＡＬ ＡＢＥＲＲＡＴＩＯＮＳ ＩＮ ＰＲＯＳＴＡＴＥ ＣＡＮＣＥＲ' ＦＲＯＮＴＩＥＲＳ ＩＮ ＢＩＯＳＣＩＥＮＣＥ Ｖ１２, 20070501, Ｐ３２８７-３３０１ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2977762A3 (en) | 2016-05-04 |
| US10267801B2 (en) | 2019-04-23 |
| EP2513651A1 (en) | 2012-10-24 |
| US20130171662A1 (en) | 2013-07-04 |
| GB0921873D0 (en) | 2010-01-27 |
| EP2977762A2 (en) | 2016-01-27 |
| CN102782497A (zh) | 2012-11-14 |
| WO2011073619A1 (en) | 2011-06-23 |
| US20150219659A1 (en) | 2015-08-06 |
| CA2807870A1 (en) | 2011-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210047697A1 (en) | Method for improved diagnosis of dysplasias | |
| KR101976219B1 (ko) | 유방암의 바이오마커 | |
| JP2000511291A (ja) | 細胞の増殖異常の測定 | |
| KR20200128110A (ko) | 고정화 세포 또는 ffpe 조직 절편으로부터 항원성을 증강한 세포핵을 탈리하는 방법 그리고 그것을 위한 항원 부활제 및 키트 | |
| CN101669032A (zh) | 通过膜联蛋白a3对前列腺癌症的自身免疫调节 | |
| US10267801B2 (en) | Assay | |
| US9213029B2 (en) | Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients | |
| US10145850B2 (en) | Assay | |
| Lüftner et al. | Discordant results obtained for different methods of HER-2/neu testing in breast cancer–a question of standardization, automation and timing | |
| CN112236677A (zh) | 直接免疫组织化学和免疫细胞化学方法 | |
| EP1416278B1 (en) | Method for improved diagnosis of dysplasias | |
| US6162606A (en) | Immunohistochemical method for the detection of defective estrogen receptors | |
| El-Kott et al. | Histogenesis of human renal cell carcinoma by using electron microscopy and immunohistochemical techniques | |
| KR20240161980A (ko) | 갑상선암의 진단을 위한 신규한 바이오 마커 | |
| WO2025137257A1 (en) | Trop2 as a biomarker for detection of epithelial cancers and predicting and monitoring responses to therapies | |
| Li et al. | A Panel of Rabbit Monoclonal Antibody Marker for Prostate Cancer | |
| JPWO2006059712A1 (ja) | ヒトステロイドサルファターゼに結合するモノクローナル抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131213 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140814 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141113 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141120 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150828 |